Mycophenolsyre Accord (Mycophenolic Acid)

Mycophenolic Acid, the active ingredient in Mycophenolsyre Accord, is an antimetabolite immunosuppressant presented as an oral formulation for oral use. It is employed to reduce the risk of organ transplant rejection and to manage selected autoimmune disorders by inhibiting lymphocyte proliferation. After absorption the drug distributes systemically, achieving therapeutic concentrations that target immune cells while maintaining a favorable pharmacokinetic profile.

GNH USA supplies Mycophenolsyre Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Mycophenolsyre Accord is an antimetabolite immunosuppressant used in conditions where immune modulation is required. - Organ transplant rejection: helps prevent acute and chronic rejection episodes after kidney, heart or liver transplantation. - Autoimmune disease: used to treat severe manifestations such as lupus nephritis and certain vasculitides. - Off‑label severe rheumatoid arthritis: may be considered when conventional disease‑modifying agents are inadequate.

Adverse reactions may occur with Mycophenolsyre Accord and should be monitored.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, may lead to dehydration. - Headache: transient cranial discomfort. - Tremor: mild shaking of hands or limbs. - Infections: increased susceptibility to bacterial, viral or fungal infections. - Elevated liver enzymes: mild transaminase rise.

Serious or Rare Side Effects: - Leukopenia or neutropenia: significant drop in white blood cells. - Anemia: reduced red blood cell count. - Severe infection: opportunistic or life‑threatening infections. - Malignancy: increased long‑term risk of certain cancers. - Teratogenicity: potential harm to a developing fetus. - Progressive multifocal leukoencephalopathy (PML): rare demyelinating disease.

Careful monitoring and patient education are essential when using Mycophenolsyre Accord. - Monitor blood counts: regular CBC to detect leukopenia or anemia. - Assess renal function: dose may need adjustment in renal impairment. - Avoid live vaccines: increased risk of vaccine‑derived infection. - Pregnancy risk: discuss potential teratogenic effects and consider alternative therapy. - Hepatic monitoring: check liver enzymes periodically. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Mycophenolsyre Accord can interact with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Azathioprine: combined use markedly increases myelosuppression. - Live vaccines: heightened risk of vaccine‑associated infection.

Moderate Interactions (Monitor Closely): - Cyclosporine or tacrolimus: may raise mycophenolic acid exposure, requiring dose adjustment. - Cholesterol‑binding resins (e.g., cholestyramine): can reduce absorption of mycophenolic acid. - Warfarin: may potentiate anticoagulant effect, monitor INR. - Antacids containing aluminum or magnesium: may interfere with drug absorption.